Patients w/ chronic hepatitis B or C w/ antiretroviral therapy; co-infected w/ HIV-1 & HCV. Closely monitor patients co-infected w/ HIV & HBV who discontinued Descovy for at least several mth after discontinuation of treatment. Patients w/ significant underlying liver disorders. Monitor patients w/ preexisting liver dysfunction including chronic active hepatitis during treatment. Wt gain & increase in blood lipid & glucose levels may occur during treatment. Mitochondrial dysfunction following exposure in utero
. Immune reactivation syndrome. Evaluate any inflammatory symptom & institute treatment when necessary. Antiretroviral-experienced patients w/ HIV-1 harbouring the K65R mutation. Concomitant use w/ a 3rd nucleoside analogue. Closely observe patient for opportunistic infections during treatment. Osteonecrosis. Nephrotoxicity. Patients w/ end stage renal disease on chronic haemodialysis. Concomitant use w/ certain anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarb & phenytoin), antimycobacterials (eg, rifampicin, rifabutin, rifapentine), boceprevir, St. John's wort (Hypericum perforatum
) & HIV PIs other than atazanavir, lopinavir & darunavir, & drugs containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil is not recommended. May impair ability to drive or operate machinery. Pregnancy & lactation.